https://www.docwirenews.com/docwire-pick/sublingual-dexmedetomidine-treatment-effect-size/amp/
Recently, sublingual dexmedetomidine was approved by the FDA for the treatment of agitation associated with schizophrenia or bipolar I or II disorder after it significantly reduced episodes compared with placebo in the pivotal SERENITY I and SERENITY II trials.